Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2010 Apr 2;5(4):e10014.
doi: 10.1371/journal.pone.0010014.

The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy

Affiliations

The HSP70 molecular chaperone is not beneficial in a mouse model of alpha-synucleinopathy

Derya R Shimshek et al. PLoS One. .

Abstract

Background: Aggregation and misfolded alpha-synuclein is thought to be central in the pathogenesis of Parkinson's disease (PD). Heat-shock proteins (HSPs) that are involved in refolding and degradation processes could lower the aggregate load of alpha-synuclein and thus be beneficial in alpha-synucleinopathies.

Methodology/principal findings: We co-overexpressed human A53T point-mutated alpha-synuclein and human HSP70 in mice, both under the control of Thy1 regulatory sequences. Behavior read-outs showed no beneficial effect of HSP70 expression in mice. In contrast, motor coordination, grip strength and weight were even worse in the alpha-synucleinopathy model in the presence of HSP70 overexpression. Biochemical analyses revealed no differences in alpha-synuclein oligomers/aggregates, truncations and phosphorylation levels and alpha-synuclein localization was unchanged in immunostainings.

Conclusion/significance: Overexpressing HSP70 in a mouse model of alpha-synucleinopathy did not lower the toxic load of alpha-synuclein species and had no beneficial effect on alpha-synuclein-related motor deficits.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: All the authors are employees of Novartis Pharma AG. The authors confirm that this does not alter their adherence to all the PloS ONE policies on sharing data and material.

Figures

Figure 1
Figure 1. Mice overexpressing human HSP70 under the control of Thy1 regulatory sequences.
A. Schematic diagram of the Thy1-HSP70 construct. B. Overview section of a Thy1-HSP70 mouse brain stained against HSP70. C. Details of brain sections from Thy1-HSP70 mice showing HSP70 expression in different brain regions. Scale bars: 200 µm. D. Co-localization of human HSP70 (green) and human α-synuclein (red) in different brain regions of double transgenic Thy1-HSP70/Thy1-haSN(A53T) mice. White arrow: Co-localization of HSP70 and α-synuclein; Red arrow: neurons expressing only human α-synuclein; Green arrow: neurons single positive for human HSP70. Scale bars: 50 µm.
Figure 2
Figure 2. Thy1-HSP70 mice appear and behave normally and are phenotypical indifferent to wildtype mice.
Measurement of weight, forelimb grip strength and motor coordination (rotating beam and rotarod) of single Thy1-HSP70 and wildtype mice. Error bars: SEM.
Figure 3
Figure 3. HSP70 overexpression in an α-synucleinopathy mouse model is not beneficial but even worsens the phenotype.
Measurement of weight, forelimb grip strength and motor coordination (rotating beam and rotarod) of single- and double-transgenic Thy1-HSP70/Thy1-haSN(A53T) mice. Asteriks indicate statistical significance (*: p<0.05, **: p<0.01; student's t-test, two-tailed). Error bars: SEM.
Figure 4
Figure 4. Biochemical analyses of soluble and pellet fraction protein extracts from spinal cord, brainstem and anterior brain reveal no difference in α-synuclein species.
A. Immunoblot of mouse spinal cord lysates detecting soluble α-synuclein monomers, oligomers/aggregates, truncations and S129-phosphorylation (P-aSN). B. Immunoblot of mouse spinal cord lysates detecting soluble HSP70. C. Immunoblot of soluble (supernatant) and pellet fractions of brainstem detecting HSP70 and α-synuclein monomers, oligomers/aggregates, truncations and S129-phosphorylation. D. Immunoblot of soluble (supernatant) and pellet fractions of anterior brain detecting HSP70 and α-synuclein monomers, truncations and S129-phosphorylation (P-aSN). β-actin was used as loading control. The size markers are indicated. E. Bar graphs representing quantitative analyses of the immunoblots shown in C and D for the α-synuclein monomers, oligomers/aggregates, truncated forms and S129-phosphorylation (P-aSN) normalized to the loading control β-actin in soluble and pellet fractions. n = 5 per genotype. Asteriks indicate statistical significance (*: p<0.05); student's t-test, two-tailed. Error bars: standard deviation.
Figure 5
Figure 5. Histological analyses reveal no difference in α-synuclein distribution/localization in the brain.
Brain sections of single and double transgenic Thy1-HSP70/Thy1-haSN(A53T) mice stained against human α-synuclein. Black arrow: cytoplasmic and nuclear α-synuclein in the CA1 area of the hippocampus and brainstem neurons. Scale bar: 100 µm.

Similar articles

Cited by

References

    1. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science. 2003;302:841. - PubMed
    1. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science. 1997;276:2045–2047. - PubMed
    1. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet. 1998;18:106–108. - PubMed
    1. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol. 2004;55:164–173. - PubMed
    1. Douglas MR, Lewthwaite AJ, Nicholl DJ. Genetics of Parkinson's disease and parkinsonism. Expert Rev Neurother. 2007;7:657–666. - PubMed

Publication types

MeSH terms